NCT05698043View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

September 26, 2023

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-386(5)

Test

DRUG

D013, D326, D337

Reference

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY